ARROWHEAD PHARMACEUTICALS, INC. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD from Q4 2018 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Arrowhead Pharmaceuticals, Inc. quarterly/annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect history and growth rate from Q4 2018 to Q4 2022.
  • Arrowhead Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending December 31, 2022 was $94.4M.
  • Arrowhead Pharmaceuticals, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2021 was $40.9M.
  • Arrowhead Pharmaceuticals, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2020 was -$78.2M, a 141% decline from 2019.
  • Arrowhead Pharmaceuticals, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2019 was $192M, a 3520% increase from 2018.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 $94.4M +$187M Oct 1, 2022 Dec 31, 2022 10-Q 2023-02-06
Q4 2021 -$92.8M -$89.1M -2434% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-06
Q4 2020 -$3.66M -$243M -102% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-02
Q4 2019 $239M +$79.6M +49.9% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-04
Q4 2018 $160M Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.